Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David W J Clark

Showing results (1-10 of 13) with videos related to

Pageof 2
Sort By:
European Journal of Clinical Pharmacology|June 8, 2006
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?David W J Clark, Johanna Strandell
BMJ (Clinical Research Ed.)|June 12, 2004
Nose bleeds associated with use of risperidoneMira Harrison-Woolrych, David W J Clark
BMJ (Clinical Research Ed.)|December 4, 2004
Sibutramine may be associated with memory impairmentDavid W J Clark, Mira Harrison-Woolrych
Expert Opinion on Drug Safety|October 27, 2004
Disturbance of vision by COX-2 inhibitorsDavid M Coulter, David W J Clark
Current Drug Safety|August 12, 2008
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactionsDavid W J Clark, Mira Harrison-Woolrych
Drug Safety|May 15, 2004
Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiologyDavid W J Clark, Deborah Layton, Saad A W Shakir
Drug Safety|December 15, 2010
Clinical implications of pharmacogenetic variation on the effects of statinsSimran D S Maggo, Martin A Kennedy, David W J Clark
European Journal of Clinical Pharmacology|May 21, 2003
Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome)David W J Clark, Ana-Maria Correa-Nunes, I Ralph Edwards
Drug Safety|November 26, 2008
Randomized controlled trials and assessment of drug safetyDavid W J Clark, David M Coulter, Frank M C Besag
Drug Safety|December 14, 2004
Linking pharmacovigilance with pharmacogeneticsDavid W J Clark, Emma Donnelly, David M Coulter, et al.
Pageof 2

Showing results (1-10 of 13) with videos related to

Sort By:
Pageof 2
European Journal of Clinical Pharmacology|June 8, 2006
Myopathy including polymyositis: a likely class adverse effect of proton pump inhibitors?David W J Clark, Johanna Strandell
BMJ (Clinical Research Ed.)|June 12, 2004
Nose bleeds associated with use of risperidoneMira Harrison-Woolrych, David W J Clark
BMJ (Clinical Research Ed.)|December 4, 2004
Sibutramine may be associated with memory impairmentDavid W J Clark, Mira Harrison-Woolrych
Expert Opinion on Drug Safety|October 27, 2004
Disturbance of vision by COX-2 inhibitorsDavid M Coulter, David W J Clark
Current Drug Safety|August 12, 2008
The role of the New Zealand Intensive Medicines Monitoring Programme in identification of previously unrecognised signals of adverse drug reactionsDavid W J Clark, Mira Harrison-Woolrych
Drug Safety|May 15, 2004
Do some inhibitors of COX-2 increase the risk of thromboembolic events?: Linking pharmacology with pharmacoepidemiologyDavid W J Clark, Deborah Layton, Saad A W Shakir
Drug Safety|December 15, 2010
Clinical implications of pharmacogenetic variation on the effects of statinsSimran D S Maggo, Martin A Kennedy, David W J Clark
European Journal of Clinical Pharmacology|May 21, 2003
Signal that reboxetine use is linked with symptoms of peripheral ischaemia (Raynaud's syndrome)David W J Clark, Ana-Maria Correa-Nunes, I Ralph Edwards
Drug Safety|November 26, 2008
Randomized controlled trials and assessment of drug safetyDavid W J Clark, David M Coulter, Frank M C Besag
Drug Safety|December 14, 2004
Linking pharmacovigilance with pharmacogeneticsDavid W J Clark, Emma Donnelly, David M Coulter, et al.
Pageof 2